HRP20211776T1 - Ligandi za integrin alfavbeta6, njihova sinteza i upotreba - Google Patents
Ligandi za integrin alfavbeta6, njihova sinteza i upotreba Download PDFInfo
- Publication number
- HRP20211776T1 HRP20211776T1 HRP20211776TT HRP20211776T HRP20211776T1 HR P20211776 T1 HRP20211776 T1 HR P20211776T1 HR P20211776T T HRP20211776T T HR P20211776TT HR P20211776 T HRP20211776 T HR P20211776T HR P20211776 T1 HRP20211776 T1 HR P20211776T1
- Authority
- HR
- Croatia
- Prior art keywords
- leu
- ala
- pro
- compound
- lys
- Prior art date
Links
- 102000006495 integrins Human genes 0.000 title claims 3
- 108010044426 integrins Proteins 0.000 title claims 3
- 230000015572 biosynthetic process Effects 0.000 title 1
- 239000003446 ligand Substances 0.000 title 1
- 238000003786 synthesis reaction Methods 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 23
- 150000002148 esters Chemical class 0.000 claims 11
- 150000003839 salts Chemical class 0.000 claims 11
- 239000012453 solvate Substances 0.000 claims 11
- 239000000825 pharmaceutical preparation Substances 0.000 claims 9
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims 4
- 239000012636 effector Substances 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical group OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 3
- 206010016654 Fibrosis Diseases 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 230000004761 fibrosis Effects 0.000 claims 3
- 239000007850 fluorescent dye Substances 0.000 claims 3
- 238000001215 fluorescent labelling Methods 0.000 claims 3
- ONIBWKKTOPOVIA-SCSAIBSYSA-N D-Proline Chemical compound OC(=O)[C@H]1CCCN1 ONIBWKKTOPOVIA-SCSAIBSYSA-N 0.000 claims 2
- 239000002202 Polyethylene glycol Substances 0.000 claims 2
- 208000036142 Viral infection Diseases 0.000 claims 2
- 238000002372 labelling Methods 0.000 claims 2
- 238000002595 magnetic resonance imaging Methods 0.000 claims 2
- 230000003287 optical effect Effects 0.000 claims 2
- 229920001223 polyethylene glycol Polymers 0.000 claims 2
- 229920001451 polypropylene glycol Polymers 0.000 claims 2
- 238000002600 positron emission tomography Methods 0.000 claims 2
- 239000002243 precursor Substances 0.000 claims 2
- 238000002603 single-photon emission computed tomography Methods 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 230000009385 viral infection Effects 0.000 claims 2
- 230000003612 virological effect Effects 0.000 claims 2
- 238000012800 visualization Methods 0.000 claims 2
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 claims 1
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- 206010058029 Arthrofibrosis Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 241000709700 Coxsackievirus A9 Species 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 208000007212 Foot-and-Mouth Disease Diseases 0.000 claims 1
- 241000710198 Foot-and-mouth disease virus Species 0.000 claims 1
- 241000709694 Human parechovirus 1 Species 0.000 claims 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000029523 Interstitial Lung disease Diseases 0.000 claims 1
- 206010073324 Keratinising squamous cell carcinoma of nasopharynx Diseases 0.000 claims 1
- 206010023774 Large cell lung cancer Diseases 0.000 claims 1
- 206010023856 Laryngeal squamous cell carcinoma Diseases 0.000 claims 1
- 108010038807 Oligopeptides Proteins 0.000 claims 1
- 102000015636 Oligopeptides Human genes 0.000 claims 1
- 206010031112 Oropharyngeal squamous cell carcinoma Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010038748 Restrictive cardiomyopathy Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000007536 Thrombosis Diseases 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 206010052428 Wound Diseases 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 1
- 210000000234 capsid Anatomy 0.000 claims 1
- 150000001720 carbohydrates Chemical class 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 claims 1
- 230000008878 coupling Effects 0.000 claims 1
- 238000010168 coupling process Methods 0.000 claims 1
- 238000005859 coupling reaction Methods 0.000 claims 1
- 239000000032 diagnostic agent Substances 0.000 claims 1
- 229940039227 diagnostic agent Drugs 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 201000010048 endomyocardial fibrosis Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 208000028654 hypopharynx squamous cell carcinoma Diseases 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 201000009546 lung large cell carcinoma Diseases 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 208000028133 nasopharyngeal squamous cell carcinoma Diseases 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 229920001542 oligosaccharide Polymers 0.000 claims 1
- 150000002482 oligosaccharides Chemical class 0.000 claims 1
- 201000002740 oral squamous cell carcinoma Diseases 0.000 claims 1
- 208000022698 oropharynx squamous cell carcinoma Diseases 0.000 claims 1
- 230000001575 pathological effect Effects 0.000 claims 1
- 238000010647 peptide synthesis reaction Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 230000002685 pulmonary effect Effects 0.000 claims 1
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 239000007790 solid phase Substances 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0056—Peptides, proteins, polyamino acids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
Claims (16)
1. Spoj, koji se veže na integrin αvβ6, kojeg prikazuje sljedeća opća formula (I):
Ciklo-(Arg-X1-Asp-X2-X3-X4-X5-X6-X7) (I)
pri čemu promjenjive skupine X1 do X7 imaju sljedeća značenja:
X1: Gly,
X2: Leu, Ile, Nle, Val, Phe,
X3: Ala,
X4: Leu, Ile, Nle, Val, Phe, Lys, Tyr, Trp,
X5: D-Pro, N-Me-D-Lys
X6: Pro, N-Me-aminokiseline, N-Me-Lys, N-Me-Lys(Ac), te
X7: Ala, Leu, Ile, Nle, Val, Phe, Tyr, Trp,
ili pri čemu podslijed -X5-X6- predstavlja mimetik β-okreta koji se razlikuje od gore navedenih značenja,
ili njihove farmaceutski prihvatljive soli, esteri, solvati, polimorfi ili modificirani oblici koje prikazuje sljedeća opća formula (II):
(X0)n1L(X8)n2
pri čemu X0 predstavlja spoj opće formule (I) kao što je specificirano gore (izuzevši jedan atom vodika kako bi se omogućilo vezanje na spojnicu), L predstavlja spojnicu, X8 predstavlja efektorski ostatak, te pri čemu se svakog od n1 i n2 neovisno bira iz raspona od 1 do 5, po mogućnosti tako da svaki od n1 i n2 predstavlja 1, pri čemu n1+n2 predstavlja broj valencija spojnice i po mogućnosti je u rasponu od 2 do 6, poželjnije 2-5.
2. Spoj ili njegove farmaceutski prihvatljive soli, esteri, solvati, polimorfi ili modificirani oblici u skladu s patentnim zahtjevom 1, pri čemu jedna ili više promjenjivih skupina X1 do X7 ima sljedeća specifična značenja:
(a) X1: Gly i/ili
(b) X2: Leu, Ile, Nle, Val i/ili
(c) X3: Ala i/ili
(d) X4: Leu, Phe, Lys, Tyr, Trp i/ili
(e) X5: D-Pro i/ili
(f) X6: Pro, N-Me-Lys, Sar, N-Me-Lys(Ac) i/ili
(g) X7: Ala, Phe, Tyr, Trp,
a preostale promjenjive skupine X1 do X7 imaju ista značenja kao što je specificirano u patentnom zahtjevu 1.
3. Spoj ili njegove farmaceutski prihvatljive soli, esteri, solvati, polimorfi ili modificirani oblici u skladu s patentnim zahtjevom 1, pri čemu se spoj bira između:
Ciklo-(Ala-Arg-Gly-Asp-Leu-Ala-Leu-D-Pro-Pro),
Ciklo-(Ala-Arg-Gly-Asp-Leu-Ala-Phe-D-Pro-Pro),
Ciklo-(Ala-Arg-Gly-Asp-Leu-Ala-Lys-D-Pro-Pro),
Ciklo-(Phe-Arg-Gly-Asp-Leu-Ala-Leu-D-Pro-Pro),
Ciklo-(Ala-Arg-Gly-Asp-Leu-Ala-Leu-D-Pro-Sar),
Ciklo-(Ala-Arg-Gly-Asp-Leu-Ala-Leu-D-Pro-(NMe)Lys),
Ciklo-(Ala-Arg-Gly-Asp-Leu-Ala-Phe-D-Pro-(NMe)Lys),
Ciklo-(Phe-Arg-Gly-Asp-Leu-Ala-Phe-D-Pro-(NMe)Lys),
Ciklo-(Phe-Arg-Gly-Asp-Leu-Ala-Tyr-D-Pro-(NMe)Lys),
Ciklo-(Phe-Arg-Gly-Asp-Leu-Ala-Trp-D-Pro-(NMe)Lys),
Ciklo-(Tyr-Arg-Gly-Asp-Leu-Ala-Phe-D-Pro-(NMe)Lys),
Ciklo-(Trp-Arg-Gly-Asp-Leu-Ala-Phe-D-Pro-(NMe)Lys), te
Ciklo-(Phe-Arg-Gly-Asp-Leu-Ala-Arg-D-Pro-(NMe)Lys).
4. Modificirani spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 3, pri čemu se spojnicu bira iz skupine koju čine etilen-glikol, polietilen-glikol (PEG), propilen-glikol, polipropilen-glikol (PPG), aminokiseline, oligopeptidi, saharidi i oligosaharidi i njihove kombinacije.
5. Modificirani spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 4, pri čemu se efektorski ostatak X8 bira između:
(i) atomske skupine pogodne za obilježavanje spoja prema ovom izumu, po mogućnosti obilježavajuće skupine namijenjene upotrebi u fluorescentnom obilježavanju, pozitronskoj emisijskoj tomografiji (PET), jednofotonskoj emisijskoj računalnoj tomografiji (SPECT), optičkoj vizualizaciji ili magnetskoj rezonanciji (MRI),
(ii) terapijski aktivne atomske skupine, čija je terapijska aktivnost po mogućnosti pogodna za liječenje raka, virusne bolesti ili fibroze, ili
(iii) atomske skupine pogodne za upotrebu kao sidrišna skupina koja spoj čini pogodnim za kovalentno ili nekovalentno vezanje na druge entitete.
6. Modificirani spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 3, pri čemu je spojnica vezana na spoj opće formule (I) preko bočnog lanca jedne od promjenjivih skupina X4, X5, X6 ili X7, po mogućnosti preko promjenjive skupine X6.
7. Modificirani spoj u skladu s patentnim zahtjevom 5, pri čemu je ostatak X8 atomska skupina pogodna za fluorescentno obilježavanje.
8. Farmaceutski pripravak koji sadrži spoj ili njegove farmaceutski prihvatljive soli, estere, solvate, polimorfe ili modificirane oblike u skladu s bilo kojim od patentnih zahtjeva 1 do 7 i jedno ili više farmaceutski prihvatljivih pomoćnih sredstava.
9. Farmaceutski pripravak koji sadrži komponentu koju se može dobiti kovalentnim vezanjem spoja ili njegovih farmaceutski prihvatljivih soli, estera, solvata, polimorfa ili modificiranih oblika u skladu s bilo kojim od patentnih zahtjeva 1 do 7 preko efektorskog ostatka X8 na veći entitet, pri čemu je veći entitet po mogućnosti nosač poput virusne kapside.
10. Spoj ili njegove farmaceutski prihvatljive soli, esteri, solvati, polimorfi ili modificirani oblici u skladu s bilo kojim od patentnih zahtjeva 1 do 7 ili farmaceutski pripravak u skladu s patentnim zahtjevom 8 ili 9, namijenjeni upotrebi u liječenju medicinskog stanja, pri čemu je integrin αvβ6 pozitivno reguliran i/ili sudjeluje u patološkom mehanizmu.
11. Spoj ili njegove farmaceutski prihvatljive soli, esteri, solvati, polimorfi ili modificirani oblici u skladu s bilo kojim od patentnih zahtjeva 1 do 7 ili farmaceutski pripravak u skladu s patentnim zahtjevom 8 ili 9, namijenjeni upotrebi u skladu s patentnim zahtjevom 10, pri čemu se medicinsko stanje bira između raka, infekcija, osobito virusnih infekcija, fibroze, disfunkcija rožnice, intersticijske plućne bolesti, tromboze, infarkta miokarda, koronarne bolesti miokarda, arterioskleroze, osteoporoze, upale, psorijaze i otvorenih rana.
12. Spoj ili njegove farmaceutski prihvatljive soli, esteri, solvati, polimorfi ili modificirani oblici u skladu s bilo kojim od patentnih zahtjeva 1 do 7 ili farmaceutski pripravak u skladu s patentnim zahtjevom 8 ili 9, namijenjeni upotrebi u skladu s patentnim zahtjevom 10 ili 11, pri čemu je medicinsko stanje koje treba liječiti rak kojeg se bira između oralnog karcinoma pločastih stanica, laringealnog karcinoma pločastih stanica, orofaringealnog karcinoma pločastih stanica, nazofaringealnog karcinoma pločastih stanica, hipofaringealnog karcinoma pločastih stanica, raka debelog crijeva, karcinoma jajnika, raka velikih stanica pluća (NSCLC) i raka želuca, virusnih infekcija koje uzrokuje virus kojeg se bira između virusa slinavke i šapa, ljudskog parehovirusa 1 i virusa coxsakie A9, ili fibroza koju se bira između plućne fibroze, cistične fibroze, idiopatske plućne fibroze, fibroze endomiokarda, Crohnove bolesti, te artrofibroze.
13. Upotreba modificiranog spoja ili njegovih farmaceutski prihvatljivih soli, estera, solvata, polimorfa ili modificiranih oblika u skladu s bilo kojim od patentnih zahtjeva 1 do 7 ili farmaceutskog pripravka u skladu s patentnim zahtjevom 8 ili 9, kao dijagnostičkog sredstva u postupku kojeg se bira između fluorescentnog obilježavanja, pozitronske emisijske tomografije (PET), jednofotonske emisijske računalne tomografije (SPECT), optičke vizualizacije i magnetske rezonancije (MRI).
14. Farmaceutski pripravak u skladu s patentnim zahtjevom 8 ili 9 ili farmaceutski pripravak namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 10 do 12, pri čemu je farmaceutski pripravak formuliran za primjenjivanje intravenskom primjenom, intramuskularnom primjenom, transdermalnom primjenom, transmukozalnom primjenom, plućnom primjenom, intranazalnom primjenom, te oralnom primjenom.
15. Postupak priprave spoja ili njegovih farmaceutski prihvatljivih soli, estera, solvata, polimorfa ili modificiranih oblika u skladu s bilo kojim od patentnih zahtjeva 1 do 7, pri čemu postupak uključuje prvi korak generiranja linearne molekule preteče tehnikama sinteze peptida u čvrstoj fazi uz pomoć Fmoc, za kojim slijedi drugi korak, pri čemu se linearnu molekulu preteču ciklizira kako bi se dobilo spoj opće formule (I),
što može uključivati dodatni korak modificiranja spoja opće formule (I) kako bi se dobilo spoj opće formule (II).
16. Naprava koju se može dobiti kovalentnim ili nekovalentnim vezanjem spoja ili njegovih farmaceutski prihvatljivih soli, estera, solvata, polimorfa ili modificiranih oblika u skladu s bilo kojim od patentnih zahtjeva 1 do 6 preko efektorskog ostatka X8 na veći entitet, pri čemu je veći entitet po mogućnosti medicinska naprava poput stenta, dijagnostičke naprave, analitičke naprave ili naprave za pročišćavanje ili razdvajanje kemijskih ili bioloških tvari.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15185868 | 2015-09-18 | ||
| EP16767269.0A EP3350222B1 (en) | 2015-09-18 | 2016-09-19 | Ligands for integrin avbeta6, synthesis and uses thereof |
| PCT/EP2016/072144 WO2017046416A1 (en) | 2015-09-18 | 2016-09-19 | LIGANDS FOR INTEGRIN AVß6, SYNTHESIS AND USES THEREOF |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HRP20211776T1 true HRP20211776T1 (hr) | 2022-02-18 |
| HRP20211776T8 HRP20211776T8 (hr) | 2022-03-18 |
Family
ID=54238209
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20211776TT HRP20211776T8 (hr) | 2015-09-18 | 2016-09-19 | Ligandi za integrin alfavbeta6, njihova sinteza i upotreba |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US10562936B2 (hr) |
| EP (1) | EP3350222B1 (hr) |
| CN (1) | CN108137694B (hr) |
| CA (1) | CA2998968C (hr) |
| ES (1) | ES2898844T3 (hr) |
| HR (1) | HRP20211776T8 (hr) |
| SI (1) | SI3350222T1 (hr) |
| WO (1) | WO2017046416A1 (hr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3090196A1 (en) | 2018-02-06 | 2019-08-15 | Klinikum Rechts Der Isar Der Technischen Universitat Munchen | Compound for intraoperative molecular bioimaging, method of making the same, use thereof in intraoperative molecular bioimaging and surgical method comprising intraoperative molecular bioimaging |
| CN115297893A (zh) * | 2020-03-12 | 2022-11-04 | 慕尼黑科技大学 | 用于在体内寻址α-v-β-6-整合素的环肽及其缀合物 |
| WO2022221144A1 (en) * | 2021-04-12 | 2022-10-20 | University Of Washington | Engineered peptides for αvβ6 integrin binding and related methods of use and synthesis |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4415310A1 (de) * | 1994-04-30 | 1995-11-02 | Merck Patent Gmbh | Cyclopeptide |
| US8617514B2 (en) | 1999-02-22 | 2013-12-31 | Georgetown University | Tumor-targeted nanodelivery systems to improve early MRI detection of cancer |
| DE19933173A1 (de) | 1999-07-15 | 2001-01-18 | Merck Patent Gmbh | Cyclische Peptidderivate als Inhibitoren des Integrins alpha¶v¶beta¶6¶ |
| AU2003293140A1 (en) | 2002-11-26 | 2004-06-18 | Gilead Sciences, Inc. | Method of drug loading in liposomes by gradient |
| US20050013854A1 (en) | 2003-04-09 | 2005-01-20 | Mannino Raphael J. | Novel encochleation methods, cochleates and methods of use |
| EP1796729A4 (en) | 2004-10-06 | 2010-12-08 | Bc Cancer Agency | LIPOSOME WITH IMPROVED ARZNE RETENTION FOR THE TREATMENT OF CANCER |
| JP2009518345A (ja) | 2005-12-07 | 2009-05-07 | テフニーシェ ウニヴェルジテート ミュンヘン | 因子ｖｉｉｉおよび因子ｖｉｉｉ様タンパク質に対する小型ペプチドおよびペプチド模倣物の親和性リガンド |
| UA100375C2 (ru) | 2007-03-30 | 2012-12-25 | Хірофумі Такеуті | Транслегочная липосома для регулирования доставки лекарственного средства |
| CN101284133B (zh) * | 2007-04-10 | 2013-03-13 | 上海市肿瘤研究所 | 注射用整合素配体修饰的载药肿瘤靶向阳离子聚合物 |
| JP5532921B2 (ja) | 2007-05-14 | 2014-06-25 | コニカミノルタ株式会社 | リポソーム |
| CN101157729B (zh) * | 2007-10-23 | 2011-01-12 | 南京大学 | 一种肿瘤坏死因子相关凋亡配体变体及其应用 |
| CN101492494A (zh) * | 2009-03-05 | 2009-07-29 | 浙江大学 | 整合素配体环肽类似物及其环化方法 |
| PL2415470T3 (pl) | 2009-03-30 | 2016-12-30 | Kompozycja liposomowa | |
| TWI415627B (zh) | 2009-12-30 | 2013-11-21 | Iner Aec Executive Yuan | 一種利用一鍋法合成可應用於癌症診斷造影與標靶治療的多功能微脂體之方法 |
| EP2729127B1 (en) | 2011-07-04 | 2018-05-02 | Statens Serum Institut | Methods for producing liposomes |
| CN103446053A (zh) | 2012-05-28 | 2013-12-18 | 复旦大学 | 一种用于多药耐药性肿瘤的靶向脂质体递药系统 |
| SG10201701063WA (en) | 2012-08-10 | 2017-04-27 | Taiho Pharmaceutical Co Ltd | Stable oxaliplatin-encapsulating liposome aqueous dispersion and method for stabilizing same |
| CN104755490B (zh) | 2012-10-22 | 2018-05-15 | 大鹏药品工业株式会社 | 弱酸性pH响应性肽和含有其的脂质体 |
| CN103520207A (zh) | 2013-10-23 | 2014-01-22 | 上海交通大学医学院附属仁济医院 | 靶向性顺铂纳米海藻酸钠脂质体 |
| US9387257B2 (en) | 2014-01-17 | 2016-07-12 | Academia Sinica | Lung cancer specific peptides for targeted drug delivery and molecular imaging |
-
2016
- 2016-09-19 SI SI201631386T patent/SI3350222T1/sl unknown
- 2016-09-19 US US15/760,119 patent/US10562936B2/en active Active
- 2016-09-19 WO PCT/EP2016/072144 patent/WO2017046416A1/en active Application Filing
- 2016-09-19 EP EP16767269.0A patent/EP3350222B1/en active Active
- 2016-09-19 CN CN201680054388.0A patent/CN108137694B/zh active Active
- 2016-09-19 ES ES16767269T patent/ES2898844T3/es active Active
- 2016-09-19 HR HRP20211776TT patent/HRP20211776T8/hr unknown
- 2016-09-19 CA CA2998968A patent/CA2998968C/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3350222A1 (en) | 2018-07-25 |
| HRP20211776T8 (hr) | 2022-03-18 |
| US10562936B2 (en) | 2020-02-18 |
| CA2998968C (en) | 2024-03-19 |
| CA2998968A1 (en) | 2017-03-23 |
| CN108137694A (zh) | 2018-06-08 |
| CN108137694B (zh) | 2022-08-12 |
| EP3350222B1 (en) | 2021-10-20 |
| ES2898844T3 (es) | 2022-03-09 |
| US20180265548A1 (en) | 2018-09-20 |
| WO2017046416A1 (en) | 2017-03-23 |
| SI3350222T1 (sl) | 2022-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20180303902A1 (en) | Engineered integrin binding peptide compositions | |
| DK2358737T3 (en) | RGD-containing PEPTIDE IMPLICATIONS AND APPLICATIONS THEREOF | |
| US10695396B2 (en) | Malignant tumor target peptide | |
| Durkan et al. | A heterodimeric [RGD-Glu-[64Cu-NO2A]-6-Ahx-RM2] αvβ3/GRPr-targeting antagonist radiotracer for PET imaging of prostate tumors | |
| CN101980718A (zh) | 治疗性的拟肽大环化合物 | |
| JP6952843B2 (ja) | がんおよび血管形成関連疾患を処置するためのＣＤ４４ｖ６由来環状ペプチド | |
| WO2006017619A2 (en) | Receptor-binding cyclic peptides and methods of use | |
| JP7395533B2 (ja) | インテグリン結合ペプチド及びその使用 | |
| WO2011079015A1 (en) | Rgd-containing cyclic peptides | |
| CN108473541A (zh) | 通过受体介导的化学疗法治疗癌症的肽化合物和肽缀合物 | |
| HRP20211776T1 (hr) | Ligandi za integrin alfavbeta6, njihova sinteza i upotreba | |
| AU2012361902B2 (en) | Integrin blocker polypeptide and use thereof | |
| CN109563135A (zh) | α(V)β(6)整合素结合肽及其使用方法 | |
| PT1751176E (pt) | Derivados ciclopeptídicos que possuem actividade anti-integrina | |
| Ye et al. | Exploring new near-infrared fluorescent disulfide-based cyclic RGD peptide analogs for potential integrin-targeted optical imaging | |
| CA3158422A1 (en) | Chromogranin a-derived peptides and uses thereof | |
| Aufort et al. | Synthesis, in vitro screening and in vivo evaluation of cyclic RGD analogs cyclized through oxorhenium and oxotechnetium coordination | |
| US11332498B2 (en) | Ligands for integrin αVβ8, synthesis and uses thereof | |
| Chen et al. | Unleashing the potential of natural biological peptide Macropin: Hydrocarbon stapling for effective breast cancer treatment | |
| ES2346595T3 (es) | Compuestos basados en peptidos radiomarcados y usos de los mismos. | |
| US9879052B2 (en) | Integrin-blocking polypeptides and uses thereof | |
| Pes et al. | Development of a fluorescent cardiomyocyte specific binding probe | |
| CN114957390A (zh) | 肿瘤靶向多肽及其应用 |